Deerfield Management Company, L.P. 的 Form 4 申報

Nuvalent, Inc.（NUVL），2026/7/17 申報

申報編號: 0001193805-26-000978
申報時間: 2026/7/17 15:27 ET
交易日: 2026/7/15
申報延遲: 2 天
10b5-1 計畫: 沒有勾選

SEC EDGAR 原文（在新分頁開啟）

這份申報列了 6 筆非衍生性交易、12 筆衍生性交易。交易後 2 天申報。

申報人

一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人	與公司的關係
Deerfield Management Company, L.P.CIK 0001009258	董事、持股 10% 以上大股東、其他：Director by Deputization
Deerfield Mgmt L.P.CIK 0001010823	董事、持股 10% 以上大股東、其他：Director by Deputization
Deerfield Partners, L.P.CIK 0001301041	董事、持股 10% 以上大股東、其他：Director by Deputization
Flynn James ECIK 0001352546	董事、持股 10% 以上大股東、其他：Director by Deputization
Deerfield Healthcare Innovations Fund, L.P.CIK 0001646981	董事、持股 10% 以上大股東、其他：Director by Deputization
Deerfield Mgmt HIF, L.P.CIK 0001665736	董事、持股 10% 以上大股東、其他：Director by Deputization
Deerfield Private Design Fund IV, L.P.CIK 0001680307	董事、持股 10% 以上大股東、其他：Director by Deputization
Deerfield Mgmt IV, L.P.CIK 0001713467	董事、持股 10% 以上大股東、其他：Director by Deputization

非衍生性證券（表 I）

普通股等股票的取得與處分，每一列是申報上的一筆。

非衍生性證券的交易
交易日	證券	交易	股數	價格	金額	持有方式
2026/7/15	Class A Common Stock	D交回公司處分	−8,299,225	$124.00^F1	−$1,029,103,900	間接
2026/7/15	Class A Common Stock	D交回公司處分	−8,299,225	$124.00^F1	−$1,029,103,900	間接
2026/7/15	Class A Common Stock	D交回公司處分	−650,000	$124.00^F1	−$80,600,000	間接
2026/7/15	Class A Common Stock	U少見代碼處分	−5,146	$124.00^F2	−$638,104	間接
2026/7/15	Class A Common Stock	U少見代碼處分	−5,146	$124.00^F2	−$638,104	間接
2026/7/15	Class A Common Stock - Restricted Stock Units	D交回公司處分	−3,444	$124.00^F5	−$427,056	間接

衍生性證券（表 II）

選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。

衍生性證券的交易
交易日	證券	交易	標的股數	單價	金額	持有方式
2026/7/15	Class A Common Stock	D交回公司處分	−2,717,627	$124.00^F1	−$336,985,748	間接
2026/7/15	Class A Common Stock	D交回公司處分	−2,717,627	$124.00^F1	−$336,985,748	間接
2026/7/15	Class A Common Stock	D交回公司處分	−43,000	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−43,000	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−20,000	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−20,000	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−15,000	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−15,000	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−3,789	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−3,789	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−4,147	–^F7	–	間接
2026/7/15	Class A Common Stock	D交回公司處分	−4,147	–^F7	–	間接

附註與備註

本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。

Pursuant to the Agreement and Plan of Merger, dated June 9, 2026 (the "Merger Agreement"), by and among (i) the Issuer, (ii) GlaxoSmithKline LLC ("Parent"), (iii) Harmony Row Acquisition Co. ("Purchaser") and (iv) solely for purposes of Section 9.14 therein, GSK plc, upon the effective time of the merger contemplated thereby (the "Merger") each share of Class A Common Stock and each share of Class B Common Stock beneficially owned by the Reporting Persons was cancelled and converted into the right to receive $124.00, in cash. The disposition or deemed disposition of such securities by the Reporting Persons pursuant to the Merger Agreement was exempted pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

表 I 有 3 筆、表 II 有 2 筆交易的價格引用這則附註。

Pursuant to the Merger Agreement, on July 15, 2026, Purchaser completed a tender offer (the "Offer") to purchase all outstanding shares of the Issuer's Class A Common Stock and Class B Common Stock. The reported shares were tendered to, and accepted by, the Purchaser in exchange for the offer price of $124.00 per share, in cash.

表 I 有 2 筆交易的價格引用這則附註。

The reported shares of Class A Common Stock were issuable under restricted stock units ("RSUs") granted to Dr. Wheeler, which were held for the benefit, and at the direction, of Deerfield Management. Pursuant to the Merger Agreement, each of the reported RSUs was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to (or deliverable under) such RSU immediately prior to the effective time of the Merger and (y) $124.00. The disposition or deemed disposition of such securities pursuant to the Merger Agreement was exempted pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

表 I 有 1 筆交易的價格引用這則附註。

Pursuant to the Merger Agreement, each option to purchase shares of Class A Common Stock that was outstanding immediately prior to the effective time of the Merger was cancelled and converted into the right of the holder to receive an amount in cash (without interest and less applicable withholding taxes) equal to the product of (x) the total number of shares subject to such stock option immediately prior to the effective time of the Merger and (y) the excess, if any, of $124.00 over the applicable exercise price per share under such stock option. The disposition or deemed disposition of such securities by the reporting Persons pursuant to the Merger Agreement was exempted pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended.

表 II 有 10 筆交易的價格引用這則附註。

備註

Prior to the consummation of the Merger, Cameron Wheeler, a partner in Deerfield Management, served as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

看 SEC EDGAR 上的完整原文（在新分頁開啟）